Skip to main content
MyDeficiencies

Human chorionic gonadotropin

Gonadotropin, fertility / ovulation-inducing agent

Also sold as Pregnyl, Novarel, Profasi.

Analyze another medication Medication directory

Findings for this medication

Research about this medication, graded for how strongly each finding can be attributed to it. Nothing here describes your own levels.

hCG is a large injected glycoprotein hormone, not an orally absorbed small molecule, so the classical GI-mediated depletion mechanisms (chelation, gastric-pH change, transporter competition, hepatic enzyme induction) that drive most drug-nutrient interactions do not apply, and the FDA label documents no CYP450 induction, inhibition, or hepatic metabolism pathway. What real, drug-specific signals do exist are narrow and mostly mechanistic rather than classical "depletion": a single 5,000 IU hCG dose measurably increases urinary calcium excretion and serum PTH in men within hours, acting directly through the renal LH/hCG receptor before any rise in sex steroids (Mortensen 2024) - a real, bounded, receptor-mediated renal calcium-wasting effect. Across the seven required physiological categories, hCG's own LH-mimetic signaling generates a reactive-oxygen-species burst as part of its normal ovulatory trigger in oocytes, while sustained high-dose exposure suppresses testicular antioxidant enzymes in animal models (two non-equivalent Tier B findings, both filed under Oxidative stress). hCG-triggered, hypoxic granulosa cells shift toward glycolytic (lactate-based) energy metabolism during luteinization (Wu 2024) - a single shared mechanistic source that touches both Mitochondrial burden and ATP production and is disclosed as one line of evidence in the Overlap map, not two independent confirmations. In ovarian hyperstimulation syndrome, ADH-mediated water retention can produce dilutional hyponatremia - a retention disturbance, not a sodium deficiency, per Hard Rule 5.

Gonadotropin, fertility / ovulation-inducing agent · ATC G03GA01 · also sold as Pregnyl and Novarel and Ovidrel (recombinant) and Profasi · reviewed 2026-09-26. This describes research about the medication. It does not say anything about your own levels or health.

How to read the evidence grades

These colours describe how strongly a finding can be attributed to the medication in the research. They are not a severity score and they say nothing about your own health.

Grades describe how strongly a finding can be attributed to Human chorionic gonadotropin in the research — not how common it is, how serious it would be, and not anything about you personally.

Red — Severe
Two or more independent Tier A sources, this drug in the cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence.
Orange — Moderate
At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit.
Yellow — Low
Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction.
Not graded — disclosed evidence gap
Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result.Source definition: Not gradeable under the rules above because nothing has been measured. Published as a documented gap, never as reassurance that there is no effect.

What the research found

Calcium - acute renal wasting after a single hCG dose

Orange — Moderate

See study details

A single 5,000 IU hCG injection significantly increases urinary calcium excretion and serum PTH within hours in men, before any rise in testosterone or estradiol - a real, receptor-mediated, acute renal effect, bounded to the hours-long window after dosing, not a chronic dietary calcium deficiency.

Full detail and limits

What the grade means here: At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit. Orange

Limits on what this shows

  • Key negative/null findings: None reported within this study; effect direction was consistent across the mouse and human arms. No second, independent Tier A source was located to corroborate the finding, which is why this is graded orange rather than red.
  • At-risk subgroups: Repeated or high-frequency hCG dosing (ovulation-induction or off-label male hypogonadism protocols); patients with pre-existing hypoparathyroidism, disordered calcium homeostasis, or QT-prolonging conditions given the observed QTc signal.
  • Counter-evidence on record: None identified; this is presently a single-source finding pending independent replication, and it reflects a single acute dose rather than chronic supplementation.

Regulatory status

Not listed as an adverse reaction in the FDA Pregnyl label; identified only in an independent 2024 mechanistic study.

Population evidence

Mortensen et al. 2024, Cell Calcium 122:102908. Translational study: C57BL/6 mice (vehicle n=12, LH n=8, LH+cinacalcet n=8) and human males (healthy men and men with hypergonadotropic or hypogonadotropic hypogonadism) given a single 5,000 IU hCG injection. Mice given LH nearly doubled urinary calcium excretion (0.98 vs 0.54 mmol/L, p=0.002). The human arm showed a significant rise in urinary calcium excretion, serum PTH, and 1,25(OH)2D3, an early transient decline in ionized calcium, and a significant prolongation of the cardiac QTc interval. Exact human group sizes were not recoverable from the accessible abstract in this review.

Mechanism

LHCGR is expressed in renal tissue; the calciuric/PTH effect preceded any measurable rise in sex steroids, indicating a direct receptor-mediated renal action rather than a downstream androgen or estrogen effect.

Counter-evidence held on record

This is a real but narrow, receptor-mediated renal calcium-wasting signal, not a general dietary calcium-deficiency claim. No calcium supplementation dose is recommended on this basis; the compensatory PTH/vitamin D response and observed QTc effect mean any supplementation decision belongs with a prescriber, especially for patients on repeated hCG dosing.

Sodium - dilutional hyponatremia in OHSS

Yellow — Low

See study details

In ovarian hyperstimulation syndrome following hCG-triggered ART cycles, ADH-mediated water retention and third-space fluid shifts can produce dilutional hyponatremia - an excess/retention disturbance, not a dietary sodium deficiency, where fluid restriction rather than sodium supplementation is the corrective action.

Full detail, limits and 1 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Key negative/null findings: Potassium remained within the normal range in this case despite the sodium disturbance, indicating a selective free-water handling problem rather than a global electrolyte depletion.
  • At-risk subgroups: Women with PCOS or high oocyte yield undergoing hCG-triggered ART cycles, i.e., those at elevated OHSS risk.
  • Counter-evidence on record: This is a single case report; population-level incidence of hyponatremia specifically (as distinct from OHSS overall) was not located.

Regulatory status

OHSS itself is a labeled serious adverse reaction of hCG; hyponatremia specifically is not named in the FDA label.

Population evidence

Elmahal, Lohana, Anvekar, Menda & Arti 2021, Cureus, DOI 10.7759/cureus.16556. Case report: 34-year-old woman with PCOS, post-IVF embryo transfer with hCG trigger, presenting with OHSS. Sodium 127 mmol/L (reference 135-145 mmol/L); potassium 4.6 mmol/L (reference 3.6-5.1 mmol/L), attributed by the authors to ADH hypersecretion from decreased effective intravascular volume plus peritoneal fluid third-spacing and hemoconcentration.

Mechanism

OHSS-driven capillary leak and relative intravascular volume depletion trigger non-osmotic ADH release, causing water retention in excess of sodium (a dilutional/hormonal disturbance).

Counter-evidence held on record

This is a water-retention/dilutional problem, not a sodium deficiency. Sodium or fluid supplementation would be the wrong response; management is fluid/electrolyte monitoring and OHSS-directed clinical care.

  • Elmahal M, Lohana P, Anvekar P, Menda MK, Arti. "Hyponatremia: An Untimely Finding in Ovarian Hyper-Stimulation Syndrome." Cureus. 2021. — Case report, hCG-triggered IVF cycle, this drug specifically. Tier B.

The five body-system areas

Each finding is counted once, in a single area. Where a study is mentioned in a second area it is context only.

Mitochondrial Burden

Each finding below is counted once, in this area only.

Mitochondrial burden - glycolytic reprogramming in hCG-triggered luteinization

Yellow — Low

See study details

In hCG-triggered, hypoxic granulosa cells, hCG signaling drives a lactate-fueled "lactylation" shift supporting luteinization - a mechanistic reprogramming of cellular energy metabolism, not a demonstrated structural mitochondrial injury.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Key negative/null findings: No mitochondrial membrane potential, ultrastructure, or biogenesis marker was reported in the accessible summary of this study; this entry does not claim structural mitochondrial injury.
  • At-risk subgroups: None established; this is preclinical, mechanistic data specific to a hypoxic follicular microenvironment.
  • Counter-evidence on record: No human granulosa-cell or clinical mitochondrial-function data specific to hCG were located despite searches across PubMed, Europe PMC, Crossref, and Semantic Scholar/OpenAlex (partly rate-limited; see Sources).

Regulatory status

Not addressed in the FDA label.

Population evidence

Wu et al. 2024, International Journal of Biological Macromolecules 280:135580. Mouse ovarian granulosa cells (in vivo and in vitro). hCG-triggered luteinization under hypoxia increased lactate production and histone/transcription-factor lactylation (H3K18la, CREB-K136la), upregulating CYP11A1 and StAR transcription; granulosa cells were shown to rely on glycolysis for energy under these conditions.

Mechanism

hCG-LHCGR-cAMP-PKA-CREB signaling, potentiated by hypoxia-driven glycolytic lactate production and its epigenetic (lactylation) signaling role - a metabolic-reprogramming mechanism, not a direct mitochondrial toxicant.

Counter-evidence held on record

This describes a metabolic-reprogramming signal in animal/cell models under hypoxia, not a demonstrated human mitochondrial injury, and should not be read as evidence that hCG depletes mitochondrial function in patients. See Overlap map: this entry shares its sole source with ATP production below.

Oxidative Stress

Each finding below is counted once, in this area only.

Oxidative stress - physiological trigger vs. chronic supraphysiological damage

Yellow — Low

See study details

hCG's own LH-mimetic signaling generates a burst of reactive oxygen species as part of its normal ovulatory-trigger mechanism, while sustained, above-label-dose exposure suppresses testicular antioxidant enzymes in rats - two mechanistically real but non-equivalent Tier B animal findings, not evidence of a general "antioxidant depletion" effect at labeled clinical doses.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Key negative/null findings: The acute ovarian ROS burst did not trigger apoptosis or DNA fragmentation, distinguishing a physiological signaling role from cellular damage in that context.
  • At-risk subgroups: None established in humans. The chronic-exposure signal derives from a research dosing regimen (100 IU/day for 30 days) that exceeds standard single-cycle ovulation-trigger or hypogonadism dosing, and may be most relevant to off-label, sustained, supraphysiological use.
  • Counter-evidence on record: No human Tier A or Tier B data measuring systemic oxidative-stress markers (e.g., serum MDA, total antioxidant capacity) in patients on labeled hCG regimens were located; both findings above rest entirely on animal data.

Regulatory status

Not addressed in the FDA label.

Population evidence (ovarian, acute)

Tiwari & Chaube 2017, BioResearch Open Access 6(1):110-122. Immature female rats given 20 IU hCG; oocyte ROS and H2O2 roughly doubled by 7h, driving meiotic resumption from diplotene arrest (68.2% of oocytes at 7h) to metaphase-II arrest (87.4% at 21h); iNOS and NO levels fell. The ROS rise was explicitly not sufficient to trigger Bax/cytochrome c expression or DNA fragmentation.

Population evidence (testicular, chronic)

Gautam et al. 2007, Apoptosis 12(7):1173-1182. Adult rats given 100 IU/day hCG for 30 days; testicular H2O2 and lipid peroxidation rose while superoxide dismutase, catalase, and glutathione-S-transferase activity fell; germ cell apoptosis increased via Fas upregulation and caspase-3 activity; serum testosterone rose transiently (peak ~day 15) then returned to baseline by day 30.

Mechanism

A physiological ROS burst is part of the LH/hCG ovulatory signaling cascade in the acute ovarian context (not tissue-damaging); chronic, supraphysiological testicular exposure appears to exhaust endogenous antioxidant enzyme capacity over weeks.

Counter-evidence held on record

Animal-only evidence, and the chronic-damage finding used a dosing regimen above standard clinical protocols. This does not establish that patients on labeled ovulation-trigger or hypogonadism dosing experience clinically meaningful oxidative stress, and no antioxidant supplementation is recommended on this basis.

Copper and Iron Balance

Copper and iron are assessed separately. Nothing here is counted twice.

Copper

Not graded — disclosed evidence gap

See study details

No study was found testing whether hCG changes copper status; the one directly relevant human dataset is correlational and cannot support a directional claim.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Why no grade: A human, hCG-cohort study exists (Sun et al. 2017, follicular fluid Zn/Cu in hCG-triggered IVF cycles) but it is a same-cohort correlational analysis with no pre/post-hCG or hCG-exposed-vs-unexposed comparator: it shows follicular copper correlating with oocyte/fertilization outcomes among women who all received hCG, not that hCG changed copper status - so it cannot support even a yellow directional claim. No circulating consumer claim specifically linking hCG to copper deficiency or excess was found in this review. Both conditions for ungraded (Step 7) are met.

Search channels tried

WebSearch (multiple phrasings), Europe PMC REST API ("chorionic gonadotropin" AND (iron OR ferritin), which also returned no copper-specific hits), PubMed listing pages. No tooling block was encountered specifically for copper queries; this reflects a genuine literature gap for a causal claim, not an access failure.

Iron

Not graded — disclosed evidence gap

See study details

No study measuring iron status, ferritin, or iron metabolism as a function of hCG exposure was located in humans or animals.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Why no grade: An Europe PMC REST API search for "chorionic gonadotropin" AND (iron OR ferritin) returned only tangential hits: a ferritin-nanoparticle immunoassay method for detecting hCG (ferritin used as a nanoparticle carrier, not measured as a biomarker), an iron-deficiency/thyroid-in-pregnancy study mentioning hCG only contextually, and a PCOS ferritin/IVF-outcome study that did not examine hCG administration itself. No circulating consumer claim specific to hCG and iron was found. Both conditions for ungraded are met.

Search channels tried

Europe PMC REST API, WebSearch (multiple phrasings including "hCG erythrocytosis iron ferritin"), and the male-hypogonadism hematocrit literature reviewed under Oxygen delivery/utilization, none of which reported iron or ferritin data alongside hematocrit.

Gut Microbiome Risk

Each finding below is counted once, in this area only.

Gut microbiome risk

Not graded — disclosed evidence gap

See study details

No study directly linking hCG (as an administered drug) to gut microbiome composition or diversity changes was located.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Why no grade: Searches across WebSearch and the Europe PMC REST API for "human chorionic gonadotropin" combined with "microbiome" or "gut bacteria" returned only unrelated maternal-pregnancy-microbiome or hyperemesis-gravidarum literature, none studying hCG as an administered drug's effect on gut microbiome composition. No circulating consumer claim linking hCG to microbiome disruption was found. Both conditions for ungraded are met.

Tooling note

A repeat Europe PMC query on this topic returned an HTTP 429 rate-limit response later in this review, after the initial WebSearch and PubMed-listing passes had already returned clean, empty-for-hCG results. The thoroughness requirement (multiple phrasings, more than one host, before settling on ungraded) was met before that limit was hit; the 429 did not by itself determine this outcome.

Oxygen and ATP Output

Oxygen delivery and ATP production are assessed separately. Nothing here is counted twice.

ATP production - glycolytic shift, not a demonstrated ATP deficit

Yellow — Low

See study details

The same hCG-triggered granulosa-cell studies showing a glycolytic (lactate) energy shift under hypoxia imply altered, not simply reduced, cellular ATP-generating pathways during luteinization; no direct human ATP measurement in hCG-exposed tissue was located.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Key negative/null findings: A frequently-cited title, "Adenosine triphosphate synthesis, mitochondrial number and activity, and pyruvate uptake in oocytes after gonadotropin injections" (Lee et al., Fertility and Sterility 2006), could not be confirmed to have used hCG specifically rather than PMSG in its "gonadotropin injection" protocol after repeated access attempts (PubMed article page, Crossref, Unpaywall, and Semantic Scholar all either blocked, rate-limited, or lacked abstract text). It is excluded from this entry's evidence base under the cohort test and listed in Sources as unverifiable.
  • At-risk subgroups: None established.
  • Counter-evidence on record: None identified beyond the exclusion above.

Regulatory status

Not addressed in the FDA label.

Population evidence

Wu et al. 2024 (same source as Mitochondrial burden, above). Granulosa cells increase glycolytic flux/lactate production under hCG-triggered, hypoxic luteinization, with lactate serving as both an energy source and an epigenetic signal, rather than showing a clear reduction in total cellular ATP.

Mechanism

Follicular hypoxia limits oxidative-phosphorylation capacity; hCG-triggered signaling appears to favor compensatory glycolytic ATP generation during luteinization.

Counter-evidence held on record

Evidence is indirect and mechanistic only, in animal/cell models. No claim of reduced ATP output or patient-level fatigue is supported, and no supplementation (e.g., CoQ10, creatine) is recommended on this basis.

Oxygen delivery/utilization - reverse-direction hematocrit finding

Yellow — Low

See study details

Contrary to the erythrocytosis expected from androgen-elevating therapies, a small retrospective series of men switched to hCG monotherapy after prior exogenous testosterone use showed a modest hematocrit decline rather than a rise - a reassuring but low-certainty, abstract-level signal.

Full detail, limits and 1 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Key negative/null findings: None reported beyond the HCT-decrease direction itself.
  • At-risk subgroups: None established; this finding is specific to hCG's male hypogonadism/monotherapy use and does not apply to its female ovulation-induction indication.
  • Counter-evidence on record: Broader testosterone-replacement literature (Tier C, class-level, not hCG-specific) documents dose-dependent erythrocytosis/polycythemia risk with exogenous testosterone - the comparator therapy this finding runs contrary to, which is why the reverse direction is notable rather than expected.

Regulatory status

Not addressed in the FDA label; OHSS and arterial thromboembolism are labeled risks but are not framed there as oxygen-delivery or hematologic-nutrient findings.

Population evidence

Rainer, Pai & Masterson 2022, The Journal of Sexual Medicine 19(4, Suppl 1), DOI 10.1016/j.jsxm.2022.01.026. Retrospective chart review of hCG monotherapy in men with prior exogenous testosterone use (~50 charts reviewed); a subset with hematocrit data (n=15) showed a statistically significant decrease in HCT after transition to hCG, with no thromboembolic events reported in the cohort. This is a conference-supplement abstract, not a full peer-reviewed manuscript; the exact HCT values retrieved varied slightly (approximately 45.0-45.3% to 43.9-44.2%) between two separate retrieval passes of the same source during this review, so figures are reported qualitatively here rather than to the decimal.

Mechanism

Not established in the source; plausibly reflects lower or more physiologic circulating testosterone under hCG monotherapy compared with injectable testosterone esters, but this was not directly tested.

Counter-evidence held on record

A single, small, abstract-level dataset. This does not establish that hCG prevents or reverses polycythemia, and hematocrit should still be monitored per standard practice for any testosterone-elevating therapy.

  • Rainer Q, Pai R, Masterson T. "Safety of Human Chorionic Gonadotropin Monotherapy for Men with Previous Exogenous Testosterone Use or Replacement Therapy." J Sex Med. 2022;19(4, Suppl 1). — Retrospective chart review, ~50 men, HCT subset n=15, this drug specifically. Conference-supplement abstract, not a full peer-reviewed manuscript; treated cautiously.Two retrieval passes of this source returned slightly different HCT decimal values in this review; figures reported qualitatively rather than to the decimal for that reason.

Claims checked and not supported

These circulate online for this medication. They are listed here only so they can be answered, never as findings, and they are not graded.

A claim with no supporting evidence is not necessarily disproven. Where evidence actually argues against a claim, that is stated below.

  • hCG (via the "hCG diet") mobilizes or redistributes stored fat, or otherwise changes metabolism to aid weight loss

    Where it comes from: Decades of hCG-diet marketing tracing to the 1954 Simeons protocol

    Why it fails: The FDA-approved label states directly that hCG "has not been demonstrated to be effective adjunctive therapy in the treatment of obesity" and has no effect on fat mobilization or appetite. An independent review (Butler & Cole 2016) found no scientific publication since the original 1954 claim supporting efficacy, and FDA/FTC have taken enforcement action against over-the-counter hCG weight-loss products as illegal.

  • The hCG diet causes vitamin/electrolyte deficiencies because of the hormone itself

    Where it comes from: Consumer diet-safety commentary conflating the hormone with the accompanying very-low-calorie diet

    Why it fails: In the detailed case located (Schunemann et al. 2021, BMJ Case Reports), the authors explicitly attribute severe hypokalemia, hypophosphatemia, and rhabdomyolysis (refeeding syndrome) to the diet's 500 kcal/day caloric restriction and subsequent carbohydrate refeeding, not to hCG, stating hCG "seems to have considerable adverse effects" of its own but not this mechanism. The electrolyte disturbance is diet-driven, not hormone-driven.

All references used above
  1. Pregnyl (chorionic gonadotropin for injection, USP) - FDA prescribing information — Regulatory label. Organon (label revision 2011). Tier A.
  2. DailyMed - Pregnyl (choriogonadotropin alfa) kit label — National Library of Medicine DailyMed. Tier A.
  3. WHO ATC/DDD Index, code G03GA01 (chorionic gonadotrophin) — WHO Collaborating Centre for Drug Statistics Methodology. DDD 250 U, parenteral.
  4. Mortensen LJ, Kooij I, Lorenzen M, et al. "Injection of luteinizing hormone or human chorionic gonadotropin increases calcium excretion and serum PTH in males." Cell Calcium. 2024;122:102908. — Translational: C57BL/6 mice + human males, single 5,000 IU hCG dose. Tier A (human arm), this drug in cohort.
  5. Tiwari M, Chaube SK. "Human Chorionic Gonadotropin Mediated Generation of Reactive Oxygen Species Is Sufficient to Induce Meiotic Exit but Not Apoptosis in Rat Oocytes." BioResearch Open Access. 2017;6(1):110-122. — Rat, 20 IU hCG, this drug specifically. Tier B.
  6. Gautam DK, Misro MM, Chaki SP, Chandra M, Sehgal N. "hCG treatment raises H2O2 levels and induces germ cell apoptosis in rat testis." Apoptosis. 2007;12(7):1173-1182. — Rat, 100 IU/day hCG x 30 days, this drug specifically. Tier B.
  7. Wu G, Pan Y, Chen M, et al. "Lactylation drives hCG-triggered luteinization in hypoxic granulosa cells." Int J Biol Macromol. 2024;280:135580. — Mouse granulosa cells, in vivo/in vitro, hCG-triggered, this drug specifically. Tier B.
  8. Rainer Q, Pai R, Masterson T. "Safety of Human Chorionic Gonadotropin Monotherapy for Men with Previous Exogenous Testosterone Use or Replacement Therapy." J Sex Med. 2022;19(4, Suppl 1). — Retrospective chart review, ~50 men, HCT subset n=15, this drug specifically. Conference-supplement abstract, not a full peer-reviewed manuscript; treated cautiously.Two retrieval passes of this source returned slightly different HCT decimal values in this review; figures reported qualitatively rather than to the decimal for that reason.
  9. Elmahal M, Lohana P, Anvekar P, Menda MK, Arti. "Hyponatremia: An Untimely Finding in Ovarian Hyper-Stimulation Syndrome." Cureus. 2021. — Case report, hCG-triggered IVF cycle, this drug specifically. Tier B.
  10. Schunemann MJ, Bertschinger M, Trachsel C, Bachli E. "Severe refeeding syndrome after human chorionic gonadotropin diet: a potentially lethal complication." BMJ Case Rep. 2021. — Case report, hCG diet, this drug specifically. Tier B; used as rebuttal (Fails verification), not as a supporting depletion claim.
  11. Butler SA, Cole LA. "Evidence for, and Associated Risks with, the Human Chorionic Gonadotropin Supplemented Diet." J Diet Suppl. 2016;13(6). — Narrative review of hCG-diet evidence and risk, this drug specifically. Used for circulating-claim audit / Fails verification.
  12. U.S. Food and Drug Administration Consumer Update, "HCG Diet Products Are Illegal" (republished via Drugs.com) — Regulatory consumer guidance; FDA/FTC enforcement position on OTC hCG weight-loss products. Tier A (regulatory).
  13. Sun Y, Lin Y, Niu M, Kang Y, Du S, Zheng B. "Follicular fluid concentrations of zinc and copper are positively associated with in vitro fertilization outcomes." Int J Clin Exp Med. 2017;10(2):3547-3553. — 53 women, hCG-triggered IVF cycles (5,000-10,000 IU), this drug specifically, but correlational with no unexposed comparator.Does not test a causal hCG-copper relationship; cited only as context for the Copper ungraded entry.
  14. Canfield RE, O'Connor JF, Birken S, Krichevsky A, Wilcox AJ. "Development of assays for the detection of pregnancy in normal and abnormal pregnancies." Environ Health Perspect. 1987;74:57-66. — Structural reference for hCG glycoprotein/CTP glycosylation and half-life determinant, accessed via a tertiary summary rather than the primary text directly.
  15. Lee ST, Oh SJ, Lee EJ, Han HJ, Lim JM. "Adenosine triphosphate synthesis, mitochondrial number and activity, and pyruvate uptake in oocytes after gonadotropin injections." Fertil Steril. 2006. DOI: 10.1016/j.fertnstert.2006.01.059. — Title-level record only.Excluded from graded entries: could not confirm hCG specifically (vs. PMSG) was the "gonadotropin" administered. PubMed article page, Fertility and Sterility full text, and Semantic Scholar/OpenAlex API calls were blocked by bot-verification or rate-limited (HTTP 429) on every attempt in this review; cohort test could not be completed.
  16. Europe PMC REST API and PubMed listing-page queries for "chorionic gonadotropin" AND iron/ferritin/copper/microbiome — Used to support the Iron, Copper, and Gut microbiome risk ungraded entries.Several repeat queries against Europe PMC, OpenAlex, Crossref, and individual PubMed/PMC article pages returned HTTP 429 rate-limit responses or reCAPTCHA bot-verification pages during this review (a shared tooling budget across parallel dossier-production sessions); disclosed per Step 4 so a later revision knows to re-check these categories. Each affected category was nonetheless searched across at least two independent channels and multiple phrasings before being marked ungraded.
  17. DrugBank and NCBI Bookshelf (StatPearls-type hCG pharmacology entry) lookups — Attempted for quantitative half-life / ADME detail beyond the FDA label.DrugBank: 404/403 across two ID guesses (no working search access without login). NCBI Bookshelf: blocked by reCAPTCHA bot-verification. Disclosed as the source of the Pharmacokinetic-basis gap on elimination route/half-life.